Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Prevention of severe premenstrual asthma attacks by leukotriene receptor antagonist
Autore:
Nakasato, H; Ohrui, T; Sekizawa, K; Matsui, T; Yamaya, M; Tamura, G; Sasaki, H;
Indirizzi:
Tohoku Univ, Sch Med, Dept Geriatr Med, Aoba Ku, Sendai, Miyagi 980, JapanTohoku Univ Sendai Miyagi Japan 980 d, Aoba Ku, Sendai, Miyagi 980, Japan Tohoku Univ, Sch Med, Dept Internal Med 1, Aoba Ku, Sendai, Miyagi 980, Japan Tohoku Univ Sendai Miyagi Japan 980 1, Aoba Ku, Sendai, Miyagi 980, Japan
Titolo Testata:
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
fascicolo: 3, volume: 104, anno: 1999,
parte:, 1
pagine: 585 - 588
SICI:
0091-6749(199909)104:3<585:POSPAA>2.0.ZU;2-C
Fonte:
ISI
Lingua:
ENG
Soggetto:
MENSTRUAL-CYCLE; MAST-CELL; INDUCED BRONCHOCONSTRICTION; 5-LIPOXYGENASE INHIBITION; RADIOIMMUNOASSAY; HISTAMINE; CHROMATOGRAPHY; PROGESTERONE; EXACERBATION; ACTIVATION;
Keywords:
menstruation; asthma; leukotrienes; glucocorticoids; female sex steroids; inflammatory cells;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
34
Recensione:
Indirizzi per estratti:
Indirizzo: Sasaki, H Tohoku Univ, Sch Med, Dept Geriatr Med, Aoba Ku, Seiryo Machi 1-1, Sendai,Miyagi 980, Japan Tohoku Univ Seiryo Machi 1-1 Sendai Miyagi Japan 980 980, Japan
Citazione:
H. Nakasato et al., "Prevention of severe premenstrual asthma attacks by leukotriene receptor antagonist", J ALLERG CL, 104(3), 1999, pp. 585-588

Abstract

Background: The etiology and treatment of premenstrual exacerbations of asthma (PMA) remain uncertain. Objective: We investigated the role of cellular mediators released from inflammatory cells in the airflow limitation during PMA. Methods: Serum levels of leukotriene (LT) B-4, LTC4, platelet-activating factor, histamine, IL-1 beta, IL-4, IL-5, IL-6, and GMCSF were measured at different time points, first just before or during menstruation when the peak expiratory flow rate (PEFR) began to decrease precipitously and second during the menstrual midcycle meek (days 10-16) when the PEFR returned to baseline values in patients with PMA and in age-matched asthma patients without PMA at the same intervals. Results: Serum levels of LTC4 were significantly higher during exacerbations of asthma than after recovery (69.0 +/- 16.0 pg/mL vs 24.0 +/- 9.5 pg/mL, P < .05), whereas those of IL-1 beta, IL-4, n-5, IL-6, GM-CSF, histamine,LTB4, and platelet-activating factor did not differ between 2 periods in 5patients with PMA, In contrast, in 5 asthmatic patients without PMA serum levels of cellular mediators did not differ between corresponding periods. Oral administration of pranlukast, an LT receptor antagonist (225 mg twice daily), significantly reduced decreases in PEFR from the baseline values (110 +/- 21 L/min with pranlukast vs 233 +/- 20 L/min without pranlukast, P <.01) in association with an improvement of asthma symptom scores (6.5 +/-.1.1 with pranlukast vs 9.8 +/- 0.7 without pranlukast, P < 0.05) in 5 patients with PMA. Conclusion: LTs are partly involved in the pathogenesis of PMA, and LT receptor antagonists may be useful for preventing airflow obstruction in patients with PMA.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 11/07/20 alle ore 13:19:37